Standard Biotools Stock Current Liabilities
| LAB Stock | USD 1.27 0.04 3.25% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Standard Biotools' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Standard Biotools Company Current Liabilities Analysis
Standard Biotools' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Standard Biotools has a Current Liabilities of 0.0. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Standard Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Biotools' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Biotools could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics of similar companies.Standard Biotools is currently under evaluation in current liabilities category among its peers.
Standard Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 276.66 M | ||||
| Shares Outstanding | 382 M | ||||
| Shares Owned By Insiders | 2.71 % | ||||
| Shares Owned By Institutions | 72.90 % | ||||
| Number Of Shares Shorted | 12.01 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 2.82 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 84.54 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Short Ratio | 7.42 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Price To Earnings To Growth | 0.31 X | ||||
| Target Price | 1.9 | ||||
| Number Of Employees | 814 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 485.13 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
| Net Asset | 612.34 M |
About Standard Biotools Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Biotools's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Biotools using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Biotools based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HLN | Haleon plc | |
| NVDA | NVIDIA | |
| INTC | Intel |
Check out Standard Biotools Piotroski F Score and Standard Biotools Altman Z Score analysis. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.